Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿病是慢性型肝炎（CHC）中纤维化进展以及对抗病毒治答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性肝（CHC）患者接受α干扰素包括派罗欣治在肝功能失代偿和死亡风险。